Available on demand
Targeted workflows have gained in popularity, especially to detect established biomarkers for several applications. An increased focus, along with technological advancements is continuously pushing the limits for high-throughput targeted analysis.
Join this webinar to explore how our customers have used the Evosep One to setup targeted workflows for clinical analysis.
THE ADDITION OF FAIMS INCREASES TARGETED PROTEOMICS SENSITIVITY FROM FFPE TUMOR BIOPSIES
Talk by Steve Sweet, Associate Director, Translational Medicine, AstraZeneca
We combined high-field asymmetric waveform ion mobility spectrometry (FAIMS) and parallel reaction monitoring (PRM) to increase assay sensitivity. FAIMS-PRM improved the overall signal-to-noise ratio over that from PRM and increased assay sensitivity for four (HER2, EGFR, cMET, and KRAS) of five proteins of clinical interest. We applied the FAIMS-PRM assay to single-section FFPE clinical samples and quantified basal HER2 expression in breast cancer samples classified as HER2 negative by immunohistochemistry. Furthermore, we determined the degree of FAIMS-dependent background reduction and showed that this correlated with an improved lower limit of quantitation with FAIMS.
HIGH-THROUGHPUT AND HIGH-SENSITIVITY BIOMARKER MONITORING IN BODY FLUID
Talk by Konstantinos Kalogeropoulos, Scientist at DTU
In this study, we report an assay utilizing the SureQuant internal standard triggered targeted method on a newest generation mass spectrometer coupled with an Evosep One liquid chromatography platform, which displays high sensitivity and a high throughput of 100 samples per day. We demonstrate the robustness of this method by quantifying proteins ranging six orders of magnitude in human wound fluid exudates, a biological fluid that exhibits sample complexity and composition similar to plasma.